BioSpace News Archive

Kyverna Therapeutics today announced the appointment of Georg Schett, M.D. and Peter A. Merkel, M.D. as Scientific Advisors.

Gate Neurosciences today announced it has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.

Ansa Biotechnologies , today announced the appointment of Jeremiah Hanes, Ph.D., as Senior Vice President (SVP) of Research & Development (R&D).

Satio, Inc today announced a strategic partnership agreement with Institut Pasteur de Dakar.

Jaguar Health today announced that its Orphan Drug Designation (ODD) application for crofelemer submitted to the U.S. Food and Drug Administration for a rare congenital diarrheal disorder called microvillus inclusion disease (MVID) has been accepted by the FDA for review.

CRIO, a Boston-based healthcare technology firm streamlining clinical trials for sponsors, sites, and patients, has been selected as the eSource vendor for a 200 patient MDD trial.

Amgen (NASDAQ: AMGN) today announced positive top-line results from the DAHLIA study, a randomized, double-blind, active-controlled, two-period crossover Phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS® (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Todos Medical, Ltd. today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. has initiated a MonkeyPox diagnostic case study series evaluating the potential for missed diagnosis among suspected MonkeyPox among non-gay male patient groups.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos”) is excited to announce the fourth annual Breathing Wellness Conference, which will take place Oct. 26-29, 2022, at the Hilton Hotel in Cancún, Mexico.

MediCardia Health Inc. with Human Longevity Inc. (San Diego, CA) to be the first in North America to offer MediCardia HeartChart, a data integration and automation platform for cardiovascular disease management and will be the first in the United States to offer the revolutionary platform that extracts the masses of data trapped in EHRs to synthesize a complete profile of a patient to proactively identify patients at risk of cardiac events.